Zimbabwe has turned down a major US health deal valued at $367m (272 million pounds) over five years over Washington's request for sensitive data.
The decision became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later explained that the United States was requesting genetic material for research and profit while was not willing to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued talks to reach a agreement suitable to both sides so the country's critical HIV programme can continue.
Wider Background
This development follows a comparable case in neighbouring Kenya, where a high court blocked a related deal with the US after legal challenges were raised about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and accountability.
As per statements, Sixteen African countries have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided significant advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," he stated.
"In essence, our nation would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens if a new pandemic arise."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining systems previously set up through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future pandemics.
"This mechanism is intended to ensure that when a country contributes its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent co-operation could be structured in a way that respects the independence and dignity of both nations."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but suggested that talks need to persist since a large portion of the country's Aids initiatives were funded by foreign aid.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it added.
This impasse underscores the ongoing tensions between receiving crucial international aid and safeguarding local interests in an increasingly interconnected world.